China Biopsy Market, Volume, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
China Biopsy Market is expected to reach US$ 7.54 Billion by 2027. Since 2000, the number of cancer cases and deaths and the crude incidence and mortality of cancer have continuously climbed in China. Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests. Furthermore, China is attempting to address its fast-rising cancer burden. However, rising population aging and the cumulative impact of risk factor exposure mean that cancer prevention faces many new obstacles.
Trends in China Biopsy Industry Prevailing Currently:
China is transitioning to developed-country cancer profiles, including high breast cancer rates, prostate cancer, lung cancer, liver cancer, thyroid cancer, colon and rectum cancer, kidney cancer, leukemia cancer, pancreatic cancer, and bladder cancer. These developments fuel a push for mass cancer screening and early detection among the 45 to 74-year-old group. As a result, China Biopsy Market Size is expected to expand at a CAGR of 6.25% during 2021-2027.
Although imaging procedures such as X-rays and CT scans can help detect areas of concern, they cannot distinguish between malignant and noncancerous cells. Consequently, a biopsy is the only reliable approach to identifying most cancers for cancer diagnosis. To lower the cancer burden in China, biopsy screening technologies and procedures have been developed. However, the most viable option in the near future may be to provide coordinated screening for high-risk locations and opportunistic screening for non-high-risk areas.
Key Companies Insights:
Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc. are among the important players profiled in our report. These market players in China contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.
How COVID-19 Affected the China Biopsy Test Industry?
The Coronavirus outbreak hit hard for China's biopsy diagnostics centers, hospitals, supply chain, and clinical trials. In addition, cancer diagnoses were being delayed, as they had been shut since the commencement of the COVID-19 pandemic, as diagnosis services and screening programs were put on halt.
Besides, during the pandemic, cancer patients also faced numerous challenges, including increased susceptibility to severe infection and interruptions in treatment or regular medical care. According to our results, the China Biopsy Test Market was negatively impacted from the end of 2019 to the beginning of 2020. However, according to our estimates, China Biopsy Market reached US$ 5.24 Billion in 2021 post recovery from the pandemic scenario.
Renub Research latest report “China Biopsy Market, Forecast By Market, Volume (Biopsy) & Diagnosed (Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Leukaemia and Bladder), Application Insights (Market, Volume (Biopsy) and Diagnosed), Companies (Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc.)” provides a detailed analysis of China Biopsy Industry.
Application Analysis –the Market has been covered from 8 viewpoints:
1. Breast Cancer
2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Kidney Cancer
7. Leukaemia
8. Bladder
Furthermore, the above mentioned application analysis have been covered from 3 viewpoints:
1. Market
2. Volume (Biopsy)
3. Diagnosed
Company Insights:
• Overview
• Initiatives/Recent Developments
• Financial Insight
Companies Covered:
1. Becton, Dickinson and Company
2. Thermo Fisher Scientific Inc
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
5. Biocept
6. Biocartis
7. Roche Diagnostics
8. Myriad Genetics Inc.
9. Qiagen
10. NeoGenomics Laboratories
11. Quest Diagnostics Inc.
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Market & Volume Analysis – China Biopsy Test
- 5.1 Market
- 5.2 Volume
- 6. Market & Volume Share Analysis – China Biopsy Test
- 6.1 Market Share
- 6.2 Volume Share
- 7. Application Analysis - China Biopsy Test Market
- 7.1 Breast Cancer
- 7.1.1 Market
- 7.1.2 Volume (Biopsy)
- 7.1.3 Diagnosed
- 7.2 Prostate Cancer
- 7.2.1 Market
- 7.2.2 Volume (Biopsy)
- 7.2.3 Diagnosed
- 7.3 Lung Cancer
- 7.3.1 Market
- 7.3.2 Volume (Biopsy)
- 7.3.3 Diagnosed
- 7.4 Liver Cancer
- 7.4.1 Market
- 7.4.2 Volume (Biopsy)
- 7.4.3 Diagnosed
- 7.5 Thyroid Cancer
- 7.5.1 Market
- 7.5.2 Volume (Biopsy)
- 7.5.3 Diagnosed
- 7.6 Kidney Cancer
- 7.6.1 Market
- 7.6.2 Volume (Biopsy)
- 7.6.3 Diagnosed
- 7.7 Colon & Rectum Cancer
- 7.7.1 Market
- 7.7.2 Volume (Biopsy)
- 7.7.3 Diagnosed
- 7.8 Pancreas Cancer
- 7.8.1 Market
- 7.8.2 Volume (Biopsy)
- 7.8.3 Diagnosed
- 7.9 Leukaemia
- 7.9.1 Market
- 7.9.2 Volume (Biopsy)
- 7.9.3 Diagnosed
- 7.10 Bladder
- 7.10.1 Market
- 7.10.2 Volume (Biopsy)
- 7.10.3 Diagnosed
- 8. Merger & Acquisition
- 9. Company Analysis
- 9.1 Becton, Dickinson and Company
- 9.1.1 Overview
- 9.1.2 Recent Developments
- 9.1.3 Financial Insight
- 9.2 Thermo Fisher Scientific Inc
- 9.2.1 Overview
- 9.2.2 Recent Developments
- 9.2.3 Financial Insight
- 9.3 Bio-Rad Laboratories
- 9.3.1 Overview
- 9.3.2 Recent Developments
- 9.3.3 Financial Insight
- 9.4 Exact Sciences (Genomic Health)
- 9.4.1 Overview
- 9.4.2 Recent Developments
- 9.4.3 Financial Insight
- 9.5 Biocept
- 9.5.1 Overview
- 9.5.2 Recent Developments
- 9.5.3 Financial Insight
- 9.6 Biocartis
- 9.6.1 Overview
- 9.6.2 Recent Developments
- 9.6.3 Financial Insight
- 9.7 Roche Diagnostics
- 9.7.1 Overview
- 9.7.2 Recent Developments
- 9.7.3 Financial Insight
- 9.8 Myriad Genetics Inc.
- 9.8.1 Overview
- 9.8.2 Recent Developments
- 9.8.3 Financial Insight
- 9.9 Qiagen
- 9.9.1 Overview
- 9.9.2 Recent Developments
- 9.9.3 Financial Insight
- 9.10 NeoGenomics Laboratories
- 9.10.1 Overview
- 9.10.2 Recent Developments
- 9.10.3 Financial Insight
- 9.11 Quest Diagnostics Inc.
- 9.11.1 Overview
- 9.11.2 Recent Developments
- 9.11.3 Financial Insight
- List of Figures:
- Figure-01: China – Biopsy Market (Million US$), 2017 – 2022
- Figure-02: China – Forecast for Biopsy Market (Million US$), 2023 – 2027
- Figure-03: China – Biopsy Volume (Million), 2017 – 2022
- Figure-04: China – Forecast for Biopsy Volume (Million), 2023 – 2027
- Figure-05: Application – Breast Cancer Market (Million US$), 2017 – 2022
- Figure-06: Application – Forecast for Breast Cancer Market (Million US$), 2023 – 2027
- Figure-07: Application – Breast Cancer Volume (Thousand), 2017 – 2022
- Figure-08: Application – Forecast for Breast Cancer Volume (Thousand), 2023 – 2027
- Figure-09: Application – Breast Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-10: Application – Forecast for Breast Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-11: Application – Prostate Cancer Market (Million US$), 2017 – 2022
- Figure-12: Application – Forecast for Prostate Cancer Market (Million US$), 2023 – 2027
- Figure-13: Application – Prostate Cancer Volume (Thousand), 2017 – 2022
- Figure-14: Application – Forecast for Prostate Cancer Volume (Thousand), 2023 – 2027
- Figure-15: Application – Prostate Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-16: Application – Forecast for Prostate Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-17: Application – Lung Cancer Market (Million US$), 2017 – 2022
- Figure-18: Application – Forecast for Lung Cancer Market (Million US$), 2023 – 2027
- Figure-19: Application – Lung Cancer Volume (Thousand), 2017 – 2022
- Figure-20: Application – Forecast for Lung Cancer Volume (Thousand), 2023 – 2027
- Figure-21: Application – Lung Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-22: Application – Forecast for Lung Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-23: Application – Liver Cancer Market (Million US$), 2017 – 2022
- Figure-24: Application – Forecast for Liver Cancer Market (Million US$), 2023 – 2027
- Figure-25: Application – Liver Cancer Volume (Thousand), 2017 – 2022
- Figure-26: Application – Forecast for Liver Cancer Volume (Thousand), 2023 – 2027
- Figure-27: Application – Liver Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-28: Application – Forecast for Liver Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-29: Application – Thyroid Cancer Market (Million US$), 2017 – 2022
- Figure-30: Application – Forecast for Thyroid Cancer Market (Million US$), 2023 – 2027
- Figure-31: Application – Thyroid Cancer Volume (Thousand), 2017 – 2022
- Figure-32: Application – Forecast for Thyroid Cancer Volume (Thousand), 2023 – 2027
- Figure-33: Application – Thyroid Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-34: Application – Forecast for Thyroid Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-35: Application – Kidney Cancer Market (Million US$), 2017 – 2022
- Figure-36: Application – Forecast for Kidney Cancer Market (Million US$), 2023 – 2027
- Figure-37: Application – Kidney Cancer Volume (Thousand), 2017 – 2022
- Figure-38: Application – Forecast for Kidney Cancer Volume (Thousand), 2023 – 2027
- Figure-39: Application – Kidney Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-40: Application – Forecast for Kidney Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-41: Application – Colon & Rectum Cance Market (Million US$), 2017 – 2022
- Figure-42: Application – Forecast for Colon & Rectum Cance Market (Million US$), 2023 – 2027
- Figure-43: Application – Colon & Rectum Cance Volume (Thousand), 2017 – 2022
- Figure-44: Application – Forecast for Colon & Rectum Cance Volume (Thousand), 2023 – 2027
- Figure-45: Application – Colon & Rectum Cance Diagnosed Volume (Number), 2017 – 2022
- Figure-46: Application – Forecast for Colon & Rectum Cance Diagnosed Volume (Number), 2023 – 2027
- Figure-47: Application – Pancreas Cancer Market (Million US$), 2017 – 2022
- Figure-48: Application – Forecast for Pancreas Cancer Market (Million US$), 2023 – 2027
- Figure-49: Application – Pancreas Cancer Volume (Thousand), 2017 – 2022
- Figure-50: Application – Forecast for Pancreas Cancer Volume (Thousand), 2023 – 2027
- Figure-51: Application – Pancreas Cancer Diagnosed Volume (Number), 2017 – 2022
- Figure-52: Application – Forecast for Pancreas Cancer Diagnosed Volume (Number), 2023 – 2027
- Figure-53: Application – Leukaemia Market (Million US$), 2017 – 2022
- Figure-54: Application – Forecast for Leukaemia Market (Million US$), 2023 – 2027
- Figure-55: Application – Leukaemia Volume (Thousand), 2017 – 2022
- Figure-56: Application – Forecast for Leukaemia Volume (Thousand), 2023 – 2027
- Figure-57: Application – Leukaemia Diagnosed Volume (Number), 2017 – 2022
- Figure-58: Application – Forecast for Leukaemia Diagnosed Volume (Number), 2023 – 2027
- Figure-59: Application – Bladder Market (Million US$), 2017 – 2022
- Figure-60: Application – Forecast for Bladder Market (Million US$), 2023 – 2027
- Figure-61: Application – Bladder Volume (Thousand), 2017 – 2022
- Figure-62: Application – Forecast for Bladder Volume (Thousand), 2023 – 2027
- Figure-63: Application – Bladder Diagnosed Volume (Number), 2017 – 2022
- Figure-64: Application – Forecast for Bladder Diagnosed Volume (Number), 2023 – 2027
- Figure-65: Becton, Dickinson and Company – Global Revenue (Million US$), 2017 – 2022
- Figure-66: Becton, Dickinson and Company – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-67: Thermo Fisher Scientific Inc – Global Revenue (Million US$), 2017 – 2022
- Figure-68: Thermo Fisher Scientific Inc – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-69: Bio-Rad Laboratories – Global Revenue (Million US$), 2017 – 2022
- Figure-70: Bio-Rad Laboratories – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-71: Exact Sciences (Genomic Health) – Global Revenue (Million US$), 2017 – 2022
- Figure-72: Exact Sciences (Genomic Health) – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-73: Biocept – Global Revenue (Million US$), 2017 – 2022
- Figure-74: Biocept – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-75: Biocartis – Global Revenue (Million US$), 2017 – 2022
- Figure-76: Biocartis – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-77: Roche Diagnostics – Global Revenue (Million US$), 2017 – 2022
- Figure-78: Roche Diagnostics – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-79: Myriad Genetics Inc. – Global Revenue (Million US$), 2017 – 2022
- Figure-80: Myriad Genetics Inc. – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-81: Qiagen – Global Revenue (Million US$), 2017 – 2022
- Figure-82: Qiagen – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-83: NeoGenomics Laboratories – Global Revenue (Million US$), 2017 – 2022
- Figure-84: NeoGenomics Laboratories – Forecast for Global Revenue (Million US$), 2023 – 2027
- Figure-85: Quest Diagnostics Inc. – Global Revenue (Million US$), 2017 – 2022
- Figure-86: Quest Diagnostics Inc. – Forecast for Global Revenue (Million US$), 2023 – 2027
- List of Tables:
- Table-01: China – Biopsy Test Market Share by Cancer Type (Percent), 2017 – 2022
- Table-02: China – Forecast for Biopsy Test Market Share by Cancer Type (Percent), 2023 – 2027
- Table-03: China – Biopsy Test Volume Share by Cancer Type (Percent), 2017 – 2022
- Table-04: China – Forecast for Biopsy Test Volume Share by Cancer Type (Percent), 2023 – 2027
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook